Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

riods was primarily the result of the recognition of product and research contract revenue from the Takeda collaboration and the recognition of licensing fee revenue for an extension fee payment under the agreement with PDL Biopharma Inc.

For the six-month period ended May 31, 2008, the Company's interest income decreased to $176,512 compared to $381,407 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's interest income decreased to $69,720 compared to $181,484 for the same period in fiscal 2007. The decrease for both periods was primarily the result of lower average cash and investment balances.

For the six-month period ended May 31, 2008, the Company's research and development costs increased to $5,933,367 compared to $4,059,931 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's research and development costs increased to $3,337,461 compared to $2,102,603 for the same period in fiscal 2007. The increases were primarily the result of an increase in staffing levels related to an overall increase in activity as the Company is preparing three products for the clinic, accompanied by increased patent and licensing activity and an increase in stock option remuneration expense.

For the six-month period ended May 31, 2008, the Company's general and administrative expenses increased to $2,170,683 compared to $1,437,009 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's general and administrative expenses increased to $1,149,402 compared to $762,673 for the same period in fiscal 2007. The increases were primarily the result of an increase in staffing levels, consulting fees, legal expenses and stock option remuneration expense.

As at May 31, 2008, ARIUS' cash and cash equivalents, and net working capital position were $8,543,124 and $5,807,638, respectively, compared with November 30, 2007 cash and cash equivale
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Memphis, TN (PRWEB) , ... July 02, 2015 ... ... in the development and manufacturing of surgical instruments in Orthopedics, announced today the ... orthopedic contract-manufacturing and the world's largest provider of surgical instruments to the Spine ...
(Date:7/1/2015)... PARK, N.C. and PARIS ... research firm AgBiome, and Genective, key developer of ... accelerate the discovery of new generations of insect ... for insect control to counter the realities of ... with Genective, aligning AgBiome,s unique insect control technology ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) ... market segments, including the molecular diagnostics industry. BCC Research reveals in its new report ... tests, lower test costs, and a growing need for better diagnostics as part of ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... MONTREAL and KIEL, Germany, September ... at the Kiel- based Collagen,Research Institute (CRI) have ... (FORTIGEL(R)) in the context of cell experiments.,Last weekend ... congress of the,Osteoarthritis Research Society International (OARSI) in ...
... NATICK, Mass., Sept. 14 Boston Scientific ... it has entered into a co-marketing agreement with Bladder ... solutions for urinary incontinence. Bladder Health Network offers ... and results analysis, helping to ensure that physicians and ...
... Italy, September 14 Health Robotics today reported,that Dr M ... across all of its I.V. Compounding Centers in Malaysia,Singapore, Indonesia, ... due diligence on 2 companies in the field of I.V.,Robotics, ... to RIVA,s,publicly announced multi-year delays in bringing their robot to ...
Cached Biology Technology:Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue 2Important Step Forward in Osteoarthritis Research: Bioactive Collagen Peptides Stimulate the Regeneration of Cartilage Tissue 3Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... is infected with hepatitis C virus (HCV). The outcome of ... many of the chronic infections will develop into liver cirrhosis ... hepatitis C, nor is there any approved vaccine for this ... Twenty to fifty percent of HCV infected patients recovers ...
... water samples for the presence of the radioactive element ... to conduct the sampling required by federal regulations. ... of the new testing method. The technique ... Research Institutes (GTRI) Environmental Radiation Center (ERC), and GTRI ...
... be able to tinker with a single amino acid ... them harmless, according to molecular biologists who say the ... cheap method of making vaccines. "We have successfully tested ... Berg professor of biochemistry and molecular biology at Penn ...
Cached Biology News:Who will recover spontaneously from hepatitis C virus infection 2Safe water: simpler method for analyzing radium in water samples cuts testing time 2Safe water: simpler method for analyzing radium in water samples cuts testing time 3Discovery may help defang viruses 2Discovery may help defang viruses 3
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Collected from sexually mature, mixed sex, mixed breed cats. Physiochemical constituents are measured to ensure lot-to-lot consistency....
Tracker Datamatrix TRxD reads any 1D and 2D barcodes within 0.5 seconds....
Donor feline serum and plasma...
Biology Products: